Skip to content

Geron GERN Research and development expense

Research and development expense at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Gilead Sciences logo
Gilead SciencesGILD
Biogen logo
BiogenBIIB
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's research and development expense?
Geron (GERN) reported research and development expense of $14.96M in Q1 2026.
How has Geron's research and development expense changed year-over-year?
Geron's research and development expense decreased by 0.8% year-over-year, from $15.08M to $14.96M.
What is the long-term trend for Geron's research and development expense?
Over 4 years (2021 to 2025), Geron's research and development expense has grown at a -4.5% compound annual growth rate (CAGR), from $85.73M to $71.43M.